Differences on the Mechanism of Action between the Radiolabeled Somatostatin Receptor Antagonist 177Lu-OPS201 and the Agonist 177Lu-DOTA-TATE: an in vitro Investigation

被引：0
|
作者：
Mansi, R. [1 ]
Santoianni-Klauer, D. [1 ]
Del Pozzo, L. [1 ]
Plas, P. [2 ]
Fani, M. [1 ]
机构：
[1] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[2] Inst Henri Beaufour, Ipsen, Les Ulis, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-024
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [31] Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
    Aurora Sainz-Esteban
    Vikas Prasad
    Christiane Schuchardt
    Carolin Zachert
    José Manuel Carril
    Richard P. Baum
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 501 - 511
  • [32] Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
    Sainz-Esteban, Aurora
    Prasad, Vikas
    Schuchardt, Christiane
    Zachert, Carolin
    Manuel Carril, Jose
    Baum, Richard P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (03) : 501 - 511
  • [33] Treatment of metastasised neuroendocrine tumours with the radiolabeled somatostatin analogues Lu-177 or Y-90-DOTA-TATE: Long term toxicity and survival in 543 patients
    Baum, R. P.
    Prasad, V.
    Hommann, M.
    Zachert, C.
    Hoersch, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S432 - S433
  • [34] Phase 1/2 Open-Label Trial to Assess the Safety and Preliminary Efficacy of 177Lu-OPS201 as Peptide Receptor Radionuclide Therapy in Patients With Somatostatin Receptor-Positive, Progressive Neuroendocrine Tumors
    Nicolas, Guillaume
    Bodei, Lisa
    Baum, Richard
    Herrmann, Ken
    Lassmann, Michael
    Hicks, Rodney
    Navalkissoor, Shaunak
    Haug, Alexander
    Oberwittler, Heike
    Wang, Tiffany
    Wild, Damian
    PANCREAS, 2018, 47 (03) : 349 - 349
  • [35] Somatostatin Receptor Theranostics in a Murine Pheochromocytoma Allograft Model: Multimodal Approaches Using [64Cu]Cu-/[177Lu]Lu-DOTA-TATE and AN-238
    Ullrich, Martin
    Bergmann, Ralf
    Peitzsch, Mirko
    Zenker, Erik
    Schally, Andrew V.
    Eisenhofer, Graeme
    Bornstein, Stefan R.
    Ziegler, Christian G.
    Pietzsch, Jens
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S201 - S201
  • [36] Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours
    Nicolas, G.
    Baum, R. P.
    Herrmann, K.
    Lassmann, M.
    Hicks, R. J.
    Haug, A. R.
    Navalkissoor, S.
    Oberwittler, H.
    Wang, T.
    Wild, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S772 - S772
  • [37] Analysis of Somatostatin Receptor Imaging Modalities and the Relationship Between Tumor Uptake and Treatment Response to [177Lu]Lu-DOTA-TATE in Patients from the Randomized Phase 3 NETTER-2 study
    Herrmann, Ken
    Ferone, Diego
    Halperin, Daniel M.
    Myrehaug, Sten
    Pavel, Marianne
    Kunz, Pamela
    Chasen, Beth
    Capdevila, Jaume
    Tafuto, Salvatore
    Oh, Do-Youn
    Yoo, Changhoon
    Falk, Stephen
    Halfdanarson, Thorvardur R.
    Folitar, Ilya
    Zhang, Yufen
    de Herder, Wouter
    Singh, Simron
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [38] Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201
    Nicolas, G.
    Baum, R.
    Herrmann, K.
    Lassmann, M.
    Hicks, R.
    Haug, A. R.
    Oberwittler, H.
    Bouterfa, H.
    Wang, T.
    Wild, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 250 - 250
  • [39] Somatostatin Receptor Expression in the Human Spleen - Answer to an Enigma by Ex vivo and In vitro Autoradiography after 177Lu-DOTA-octreotate Administration
    Melis, M.
    Kaemmerer, D.
    de Swart, J.
    Kulkarni, H. R.
    Lupp, A.
    Saenger, J.
    Groen, H. C.
    Konijnenberg, M. W.
    van der Graaf, L. M.
    de Jong, M.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S200 - S200
  • [40] Safety and Response of an Evans Blue-Modified Radiolabeled Somatostatin Analogue 177LU-Dota-Eb-Tate with Increased Effective Dose in the Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective Study
    Liu, Qingxing
    Cheng, Yuejuan
    Zang, Jie
    Wang, Hao
    Sui, Huimin
    Zhang, Jingling
    Jacobson, Orit
    Zhu, Zhaohui
    Chen, Xiaoyuan
    PANCREAS, 2020, 49 (03) : 476 - 476
12345